Marksans Pharma rises after its arm gets Marketing Authorization for Levonorgestrel Tablets from UK MHRA
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Marksans Pharma is currently trading at Rs. 205.75, up by 0.30 points or 0.15% from its previous closing of Rs. 205.45 on the BSE.
The scrip opened at Rs. 204.00 and has touched a high and low of Rs. 211.55 and Rs. 199.95 respectively. So far 74437 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 216.75 on 01-Aug-2024 and a 52 week low of Rs. 93.85 on 18-Sep-2023.
Last one week high and low of the scrip stood at Rs. 216.75 and Rs. 199.95 respectively. The current market cap of the company is Rs. 9326.11 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 22.34% and 33.78% respectively.
Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
